Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | NHERF1 | O14745 | 2/20 | 0.51 |
| ▸ | PLD2 | O14939 | 1/20 | 0.50 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.50 |
| ▸ | PYGL | P06737 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5680312 | 0.94 | NHERF1 (0.54) | ITGB3ITGA2BHDAC2KDM4EHSD17B10 | |
| SCHEMBL5896655 | 0.94 | KDM4E (0.51) | ITGB3ITGA2BHDAC2KDM4EHSD17B10 | |
| SCHEMBL5889537 | 0.92 | KDM4E (0.51) | ITGB3ITGA2BHDAC2KDM4EHSD17B10 | |
| SCHEMBL5889562 | 0.90 | HDAC2 (0.50) | ITGB3ITGA2BHDAC2KDM4EHSD17B10 | |
| SCHEMBL5889522 | 0.89 | KDM4E (0.53) | ITGB3ITGA2BHDAC2KDM4EHSD17B10 | |
| SCHEMBL5679912 | 0.89 | MMP13 (0.62) | ITGB3ITGA2BHDAC2KDM4EHSD17B10 | |
| SCHEMBL5896783 | 0.87 | ITGB3 (0.58) | ITGB3ITGA2BHDAC2KDM4EHSD17B10 | |
| SCHEMBL5889622 | 0.87 | ITGB3 (0.53) | ITGB3ITGA2BHDAC2KDM4EHSD17B10 | |
| SCHEMBL5889814 | 0.87 | HDAC2 (0.50) | ITGB3ITGA2BHDAC2KDM4EHSD17B10 | |
| SCHEMBL5889830 | 0.87 | KDM4E (0.57) | ITGB3ITGA2BHDAC2KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141680-B2 | Aromatic compounds possessing antifungal or antibacterial activity | GENELABS TECHNOLOGIES, INC. | 2006-11-28 | — | — | US | disclosed |
| EP-1556035-A4 | NOVEL AROMATIC COMPOUNDS POSSESSING ANTIFUNGAL OR ANTIBACTERIAL ACTIVITY | GENELABS TECH INC (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1556035-A2 | NOVEL AROMATIC COMPOUNDS POSSESSING ANTIFUNGAL OR ANTIBACTERIAL ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004026264-A2 | NOVEL AROMATIC COMPOUNDS POSSESSING ANTIFUNGAL OR ANTIBACTERIAL ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20040063645-A1 | Novel aromatic compounds possessing antifungal or antibacterial activity | SMITHKLINE BEECHAM CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063645-A1 | Novel aromatic compounds possessing antifungal or antibacterial activity | ZC3HAV1, TYR, ZC3HAV1L | ITGB3 4436/4885ITGA2B 4759/4885HDAC2 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.